| Document |
Document Title |
|
WO/2022/109329A1 |
Redox active polycyclic compounds and related electrode material, electrode chemical cell battery, methods and systems are described. In particular, tricyclic compounds having a redox potential of 0.20 V to 2.0 V with reference to Zn/Zn2...
|
|
WO/2022/100717A1 |
Disclosed are a leukocyte classification reagent and kit, a classification method, an erythrocyte analysis reagent and kit, and an analysis method. Both the leukocyte classification reagent and the erythrocyte analysis reagent comprise a...
|
|
WO/2022/101352A1 |
The present invention relates to novel compounds that bind to the prostate-specific membrane antigen (PSMA)-binding and their use in the diagnosis and treatment of certain diseases where PSMA is upregulated.
|
|
WO/2022/103031A1 |
Provided is a triazine or pyrimidine derivative that contributes to a substantial improvement in lifespan of an organic electroluminescent element by effectively absorbing high energy in the UV range from an external light source to mini...
|
|
WO/2022/099357A1 |
Disclosed are salts of N-Cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl) methyl) pyridin-2-yl) amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine and polymorphs thereof, which are inhibitors of protein kinases, in particular cyclin-dep...
|
|
WO/2022/104348A1 |
This invention relates to compounds of Formula I that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventing or treat...
|
|
WO/2022/100716A1 |
Disclosed are a cyanine compound, a dye containing the cyanine compound, and the use of the cyanine compound. The cyanine compound has a structure of general formula I, wherein X is selected from a group consisting of C(CH3)2, O, S and S...
|
|
WO/2022/099659A1 |
Provided are a leukocyte classification reagent, reagent kit, and classification method, and an erythrocyte analysis reagent, reagent kit, and analysis method. Each of the leukocyte sorting reagent and the erythrocyte analysis reagent co...
|
|
WO/2022/100710A1 |
This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for t...
|
|
WO/2022/101412A1 |
Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhib...
|
|
WO/2022/099658A1 |
Disclosed in the present invention are a cyanine compound, a dye containing the cyanine compound, and an application of the cyanine compound. The cyanine compound has the structure of general formula I. X is selected from a group consist...
|
|
WO/2022/103411A1 |
The present disclosure relates to 1-(2-(4-cyclopropyl-1H-l,2,3- triazol-l-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carbo
xamide derivatives and structurally related compounds as VHL inhibitors for the treatment of e.g. anemia (e.g. c...
|
|
WO/2022/103960A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/099011A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is...
|
|
WO/2022/098843A1 |
Provided are heterobifunctional degrader compounds that bind with cyclin dependent kinase 9 (CDK9) and E3 ubiquitin ligase. Also provided are methods of treating a subject for a CDK9-mediated disease by administering a therapeutically ef...
|
|
WO/2022/098108A1 |
The present invention relates to an NLRP3 protein degradation inducing compound. Specifically, the present invention relates to a bifunctional compound in which an NLRP3 protein-binding moiety and an E3 ubiquitin ligase-binding moiety ar...
|
|
WO/2022/098625A1 |
The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use ...
|
|
WO/2022/091056A1 |
The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and me...
|
|
WO/2022/092141A1 |
The present invention provides: a compound, or a pharmaceutically acceptable salt thereof, having an antiviral activity and represented by formula (I); and a pharmaceutical composition containing the same. (In the formula, the broken lin...
|
|
WO/2022/092084A1 |
The present invention provides a novel fused heterocycle derivative or an agriculturally acceptable salt thereof and an herbicide containing the same as an active ingredient. Provided are a fused heterocycle derivative represented by g...
|
|
WO/2022/089593A1 |
The present application relates to the technical field of pharmaceutical chemistry, and in particular relates to a double salt compound of a flavone glycoside-organic amine anti-tumor agent, a preparation method therefor and the use ther...
|
|
WO/2022/089225A1 |
Provided in the present invention are a compound of general formula I or a pharmaceutically acceptable salt, a stereoisomer, an ester, a prodrug and a solvate thereof, a preparation method therefor and the use thereof, and in particular,...
|
|
WO/2022/092967A1 |
Disclosed are a compound represented by chemical formula 1, a photovoltaic device including same, and an image sensor.
|
|
WO/2022/094409A1 |
Described herein are crystalline forms of compounds that are deoxycytidine kinase (dCK) inhibitors, methods of making such crystalline forms, pharmaceutical compositions and medicaments comprising such crystalline forms, and methods of u...
|
|
WO/2022/092180A1 |
To solve a food crisis associated with an increase in world population expected in the near future, the creation of novel herbicides having high safety for crops and excellent herbicidal activity against weeds is desired. The problem is ...
|
|
WO/2022/083617A1 |
The present invention relates to an acetazolamide derivative, and a preparation method therefor and the use thereof in the preparation of a drug for treating coronary heart disease. The acetazolamide derivative is a type of acetazolamide...
|
|
WO/2022/083703A1 |
This disclosure relates to LPA antagonists of Formula (I) : including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
|
|
WO/2022/087326A1 |
Provided herein are Heterocyclic Compounds of formula (I), formula (II), formula (III), formula (IlIa), formula (Mb), formula (IIIc), formula (Hid), formula (IV), formula (IVa), formula (IVb), and formula (IVc), and pharmaceutically acce...
|
|
WO/2022/086284A1 |
Provided are: a compound of chemical formula 1, having inhibitory activity against protein kinase, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a use thereof.
|
|
WO/2022/083853A1 |
The present invention relates to novel free fatty acid receptor (FFAR) agonists (I), in particular agonists of FFAR1, and to the use of said FFAR agonists as medicaments, in particular for treatment and/or prevention of conditions or dis...
|
|
WO/2022/078309A1 |
Provided are a substituted bis(pyridin-2-yl)amine derivative represented by formula (I), a pharmaceutically acceptable salt, solvate, stereoisomer, prodrug and pharmaceutical composition thereof, and a medical application thereof. The de...
|
|
WO/2022/080696A1 |
Provided is a high-refractive-index benzazole derivative that effectively absorbs a high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contribute...
|
|
WO/2022/078152A1 |
A benzimidazolone GLP-1 receptor agonist and the use thereof.
|
|
WO/2022/078971A1 |
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregat...
|
|
WO/2022/078414A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
|
|
WO/2022/078306A1 |
The present invention relates to the technical field of organic synthesis and chemical catalysis. Disclosed are a large steric hinderance palladium-nitrogen-heterocyclic carbene complex, a preparation method for same, applications of sam...
|
|
WO/2022/077095A1 |
Provided are methods for treating diseases or conditions associated with Nav1.6 activity in a patient, comprising administering to said patient (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-me
thyl-N(thiazol-4-yl)benzenesulfo...
|
|
WO/2022/077094A1 |
Provided herein are certain pharmaceutical compositions comprising (S)-4-(( 1 -benzylpyrrolidin-3 -yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzene
sulfonamide (Compound A), or a pharmaceutically acceptable salt thereof, and a...
|
|
WO/2022/081807A1 |
The present invention provides acyl sulfonamide compounds of general formula (I): in which R1, R2, R3, R4, R5, R6· Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for pre...
|
|
WO/2022/079290A2 |
The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target pro...
|
|
WO/2022/076764A1 |
The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...
|
|
WO/2022/076628A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...
|
|
WO/2022/076662A1 |
The present disclosure relates to compounds of Formula (I); and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2022/073904A1 |
This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
|
|
WO/2022/074587A1 |
The present disclosure relates to a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and...
|
|
WO/2022/074588A1 |
The present disclosure provides a compound having the structure: Formula (I) wherein R1 is –H or –(alkyl); R2 is -(alkyl)-CO2H or -(alkyl)-CO2-(alkyl); R3 is –H or –(alkyl); and X is -Br or -I, or a pharmaceutically acceptable sa...
|
|
WO/2022/071484A1 |
The present invention relates to 3-hydroxyoxindole derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also...
|
|
WO/2022/070023A1 |
An object of the present disclosure is to provide a piperazine compound or the salt thereof that controls pests. The present disclosure provides a piperazine compound represented by Formula (I), or a salt thereof, wherein R1 represents a...
|
|
WO/2022/070289A1 |
This compound, or salt thereof, is represented by general formula (1), exhibits excellent IRAK-4 inhibitory activity and is useful as an active ingredient of a medicine for preventing and/or treating a disease which pertains to IRAK-4 in...
|
|
WO/2022/068930A1 |
The present invention relates to a novel compound, which effectively antagonizes P2X3 receptors and is represented by formula (I), a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug thereof, and a pre...
|
